{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:48Z","timestamp":1792788288189,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"NIH\/NCI","award":["CA138239-02"],"award-info":[{"award-number":["CA138239-02"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"DOD","award":["W81XWH-09-1-0031 01"],"award-info":[{"award-number":["W81XWH-09-1-0031 01"]}]},{"name":"State of Texas Rare and Aggressive Breast Cancer Research Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab, combined with chemotherapy, is the current standard treatment for both metastatic and early-stage HER2-positive (HER2\u2009+) breast cancer. One of the mechanisms of action of trastuzumab is antibody-dependent cellular cytotoxicity (ADCC), which involves engaging Fc\u03b3RIIIA (CD16) on natural killer (NK) cells. A competent immune system and properly functioning NK cells are crucial for effective ADCC, as they can influence favorable clinical outcomes. Resistance to trastuzumab often develops after about one year. We previously reported that elevated levels of miR-19a-3p in the serum of patients with metastatic HER2\u2009+\u2009breast cancer treated with trastuzumab were associated with a favorable prognosis. Here, we aim to identify the mechanism and the immune cells responsible for elevated serum levels of miR-19a-3p.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Peripheral blood mononuclear cells (PBMCs) from healthy individuals were used to isolate na\u00efve CD4\u2009+\u2009T cells and NK cells. Na\u00efve CD4\u2009+\u2009T cells were polarized into CD4\u2009+\u2009Th1 and CD4\u2009+\u2009Th2 cells. NK cells were utilized for the ADCC assay. Levels of transcription factors, cytokines, and miR-19a-3p were measured using RT-qPCR. Surface markers and cytokines were analyzed by flow cytometry to characterize immune cell phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In vitro NK cell-mediated ADCC resulted in increased levels of miR-19a-3p released into the supernatants after killing breast cancer cells. In vitro polarized CD4\u2009+\u2009Th1 cells expressed and secreted higher levels of miR-19a-3p than CD4\u2009+\u2009Th2 cells. Over a long-term in vitro culture (24\u00a0days), anti-CD3\/CD28 restimulation sustained higher levels of miR-19a-3p in CD4\u2009+\u2009Th1 cells compared to CD4\u2009+\u2009Th2 cells and their respective supernatants. CD4\u2009+\u2009Th1 cells developed a central memory T (T\n                      <jats:sub>CM<\/jats:sub>\n                      ) phenotype (CD45RO\u2009+\u2009CCR7\u2009+\u2009CD62L\u2009+) and expressed and secreted higher levels of miR-19a-3p than CD4 + Th2 cells. In patients with HER2\u2009+\u2009metastatic breast cancer, those with elevated serum levels of miR-19a-3p and a favorable prognosis had a larger percentage of circulating activated T cells and NK cells in their blood compared to patients with lower serum levels of miR-19a-3p and a poor prognosis. The small cohort (n\u2009=\u200915) limits the statistical power of our retrospective study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings suggest that elevated levels of miR-19a-3p in the serum of patients with HER2\u2009+\u2009metastatic breast cancer may result from effective NK cell-mediated ADCC and activation of CD4\u2009+\u2009Th1 cells, which could be responsible for the anti-tumor immune response associated with a favorable prognosis. Blood levels of miR-19a-3p might help identify breast cancer patients who have effective trastuzumab-induced anti-tumor immune responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-025-02174-8","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:02:27Z","timestamp":1769382147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High levels of circulating miR-19a-3p in patients with metastatic HER2\u2009+\u2009breast cancer are associated with a favorable prognosis and anti-tumor immune responses"],"prefix":"10.1186","volume":"28","author":[{"given":"Evan N.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda","family":"Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-7587","authenticated-orcid":false,"given":"Simone","family":"Anfossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"1","key":"2174_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2174_CR2","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"4905","key":"2174_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"issue":"10075","key":"2174_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2.","journal-title":"Lancet"},{"issue":"11","key":"2174_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"2174_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2174_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"2174_CR8","doi-asserted-by":"crossref","unstructured":"Igietseme JU, Zhu XP, Black CM. Fc Receptor-Dependent Immunity. Antibody Fc: Linking Adaptive and Innate Immunity. 2014:269\u201381.","DOI":"10.1016\/B978-0-12-394802-1.00015-7"},{"issue":"21","key":"2174_CR9","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1158\/1078-0432.CCR-07-0865","volume":"13","author":"JM Roda","year":"2007","unstructured":"Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13(21):6419\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0865.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2174_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/0008-5472.CAN-05-2429","volume":"66","author":"JM Roda","year":"2006","unstructured":"Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006;66(1):517\u201326.","journal-title":"Cancer Res"},{"issue":"17","key":"2174_CR11","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108(17):7142\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2174_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","volume":"18","author":"S Park","year":"2010","unstructured":"Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18(2):160\u201370.","journal-title":"Cancer Cell"},{"issue":"2","key":"2174_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259\u201367.","journal-title":"Br J Cancer"},{"issue":"17","key":"2174_CR14","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","volume":"10","author":"R Gennari","year":"2004","unstructured":"Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0225.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2174_CR15","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","volume":"67","author":"S Varchetta","year":"2007","unstructured":"Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007;67(24):11991\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"2174_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13058-015-0584-1","volume":"17","author":"J Datta","year":"2015","unstructured":"Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, et al. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res. 2015;17(1):71.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"2174_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050\u20139.","journal-title":"Nat Med"},{"issue":"8","key":"2174_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","volume":"54","author":"KL Knutson","year":"2005","unstructured":"Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54(8):721\u20138.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2174_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8(1):235.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"2174_CR20","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","volume":"70","author":"R Bos","year":"2010","unstructured":"Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368\u201377.","journal-title":"Cancer Res"},{"key":"2174_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","volume":"117","author":"GM Konjevic","year":"2019","unstructured":"Konjevic GM, Vuletic AM, Mirjacic Martinovic KM, Larsen AK, Jurisic VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30\u201340.","journal-title":"Cytokine"},{"issue":"10371","key":"2174_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"Lancet"},{"issue":"9816","key":"2174_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(11)61847-3.","journal-title":"Lancet"},{"issue":"1","key":"2174_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol"},{"issue":"10087","key":"2174_CR25","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(16)32417-5.","journal-title":"Lancet"},{"issue":"29","key":"2174_CR26","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/JCO.2014.57.6132","volume":"32","author":"NL Henry","year":"2014","unstructured":"Henry NL, Schott AF, Hayes DF. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility. J Clin Oncol. 2014;32(29):3207\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2174_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-022-01587-z","volume":"25","author":"SL de Haas","year":"2023","unstructured":"de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, et al. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 2023;25(1):2.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"2174_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2217\/fon-2015-0025","volume":"12","author":"T Triulzi","year":"2016","unstructured":"Triulzi T, Bianchi GV, Tagliabue E. Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. Future Oncol. 2016;12(11):1413\u201328.","journal-title":"Future Oncol"},{"issue":"7","key":"2174_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2174_CR30","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","volume":"15","author":"G Bianchini","year":"2014","unstructured":"Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58-68.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2174_CR31","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/annonc\/mdv395","volume":"26","author":"G Bianchini","year":"2015","unstructured":"Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol. 2015;26(12):2429\u201336. https:\/\/doi.org\/10.1093\/annonc\/mdv395.","journal-title":"Ann Oncol"},{"issue":"1","key":"2174_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jnci\/djy076","volume":"111","author":"M Ignatiadis","year":"2019","unstructured":"Ignatiadis M, den Van Eyn G, Roberto S, Fornili M, Bareche Y, Desmedt C, et al. Tumor-infiltrating lymphocytes in patients receiving Trastuzumab\/Pertuzumab-based chemotherapy: a TRYPHAENA substudy. J Natl Cancer Inst. 2019;111(1):69\u201377.","journal-title":"J Natl Cancer Inst"},{"key":"2174_CR33","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2174_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397. https:\/\/doi.org\/10.1016\/s0092-8674(04)00045-5.","journal-title":"Cell"},{"issue":"2","key":"2174_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"issue":"9","key":"2174_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41571-018-0035-x","volume":"15","author":"S Anfossi","year":"2018","unstructured":"Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. 2018;15(9):541\u201363.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2174_CR37","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/cdd.2013.125","volume":"20","author":"E Mogilyansky","year":"2013","unstructured":"Mogilyansky E, Rigoutsos I. The miR-17\/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20(12):1603\u201314.","journal-title":"Cell Death Differ"},{"key":"2174_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2018.02.035","volume":"423","author":"D Baumjohann","year":"2018","unstructured":"Baumjohann D. Diverse functions of miR-17-92 cluster microRNAs in T helper cells. Cancer Lett. 2018;423:147\u201352. https:\/\/doi.org\/10.1016\/j.canlet.2018.02.035.","journal-title":"Cancer Lett"},{"key":"2174_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-5876-8-17","volume":"8","author":"K Sasaki","year":"2010","unstructured":"Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, et al. miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med. 2010;8:17.","journal-title":"J Transl Med"},{"issue":"9","key":"2174_CR40","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nri3494","volume":"13","author":"D Baumjohann","year":"2013","unstructured":"Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol. 2013;13(9):666\u201378.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2174_CR41","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.4049\/jimmunol.1202018","volume":"191","author":"FL Locke","year":"2013","unstructured":"Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013;191(4):1677\u201385. https:\/\/doi.org\/10.4049\/jimmunol.1202018.","journal-title":"J Immunol"},{"issue":"1","key":"2174_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083113","volume":"9","author":"S Anfossi","year":"2014","unstructured":"Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE. 2014;9(1):e83113. https:\/\/doi.org\/10.1371\/journal.pone.0083113.","journal-title":"PLoS ONE"},{"issue":"10","key":"2174_CR43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani JA, Smyth MJ. Functional significance of the perforin\/granzyme cell death pathway. Nat Rev Immunol. 2002;2(10):735\u201347.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2174_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1172\/JCI0215950","volume":"110","author":"R Parihar","year":"2002","unstructured":"Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002;110(7):983\u201392.","journal-title":"J Clin Invest"},{"issue":"2","key":"2174_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133\u201346.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2174_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","volume":"44","author":"V Niederlova","year":"2023","unstructured":"Niederlova V, Tsyklauri O, Kovar M, Stepanek O. IL-2-driven CD8(+) T cell phenotypes: implications for immunotherapy. Trends Immunol. 2023;44(11):890\u2013901. https:\/\/doi.org\/10.1016\/j.it.2023.09.003.","journal-title":"Trends Immunol"},{"issue":"10","key":"2174_CR47","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1002\/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J","volume":"31","author":"WE Carson","year":"2001","unstructured":"Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2\/neu-positive breast cancer cells. Eur J Immunol. 2001;31(10):3016\u201325.","journal-title":"Eur J Immunol"},{"issue":"5","key":"2174_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"269","key":"2174_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal"},{"issue":"23","key":"2174_CR50","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137.","journal-title":"Cancer Res"},{"issue":"5-6","key":"2174_CR51","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6690114","volume":"79","author":"J Kurebayashi","year":"1999","unstructured":"Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79(5\u20136):707\u201317. https:\/\/doi.org\/10.1038\/sj.bjc.6690114.","journal-title":"Br J Cancer"},{"issue":"5","key":"2174_CR52","first-page":"1671","volume":"6","author":"JM Reuben","year":"2000","unstructured":"Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res. 2000;6(5):1671\u20137.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2174_CR53","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162\u201371.","journal-title":"J Clin Oncol"},{"key":"2174_CR54","doi-asserted-by":"crossref","unstructured":"Baselga J. Treatment of HER2-overexpressing breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO. 2010;21 Suppl 7:vii36\u201340.","DOI":"10.1093\/annonc\/mdq421"},{"issue":"7","key":"2174_CR55","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1093\/annonc\/mdr484","volume":"23","author":"DM Collins","year":"2012","unstructured":"Collins DM, O\u2019Donovan N, McGowan PM, O\u2019Sullivan F, Duffy MJ, Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2012;23(7):1788\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdr484.","journal-title":"Ann Oncol"},{"issue":"8","key":"2174_CR56","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","volume":"15","author":"L Coenon","year":"2024","unstructured":"Coenon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M. Natural killer cells at the frontline in the fight against cancer. Cell Death Dis. 2024;15(8):614.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2174_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.imlet.2014.05.004","volume":"161","author":"E Kobayashi","year":"2014","unstructured":"Kobayashi E, Motoi S, Sugiura M, Kajikawa M, Kojima S, Kohroki J, et al. Antibody-dependent cellular cytotoxicity and cytokine\/chemokine secretion by KHYG-1 cells stably expressing FcgammaRIIIA. Immunol Lett. 2014;161(1):59\u201364.","journal-title":"Immunol Lett"},{"key":"2174_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","volume":"60","author":"P Mando","year":"2021","unstructured":"Mando P, Rivero SG, Rizzo MM, Pinkasz M, Levy EM. Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era. Breast. 2021;60:15\u201325. https:\/\/doi.org\/10.1016\/j.breast.2021.08.007.","journal-title":"Breast"},{"issue":"6754","key":"2174_CR59","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708\u201312.","journal-title":"Nature"},{"issue":"1","key":"2174_CR60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri3567","volume":"14","author":"DL Farber","year":"2014","unstructured":"Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24\u201335.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2174_CR61","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41590-023-01510-4","volume":"24","author":"M Kunzli","year":"2023","unstructured":"Kunzli M, Masopust D. CD4(+) T cell memory. Nat Immunol. 2023;24(6):903\u201314.","journal-title":"Nat Immunol"},{"issue":"2","key":"2174_CR62","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2015.5482","volume":"2","author":"J Datta","year":"2016","unstructured":"Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, et al. Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring. JAMA Oncol. 2016;2(2):242\u20136.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2174_CR63","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, Munz C. CD4(+) T cells in cancer. Nat Cancer. 2023;4(3):317\u201329.","journal-title":"Nat Cancer"},{"issue":"11","key":"2174_CR64","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","volume":"127","author":"JA Wagner","year":"2017","unstructured":"Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127(11):4042\u201358. https:\/\/doi.org\/10.1172\/JCI90387.","journal-title":"J Clin Invest"},{"issue":"2","key":"2174_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","volume":"232","author":"R Nahta","year":"2006","unstructured":"Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232(2):123\u201338.","journal-title":"Cancer Lett"},{"key":"2174_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1479-5876-6-25","volume":"6","author":"A Beano","year":"2008","unstructured":"Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6:25.","journal-title":"J Transl Med"},{"issue":"3","key":"2174_CR67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-24-0384","volume":"13","author":"NA Maskalenko","year":"2025","unstructured":"Maskalenko NA, Zahroun S, Tsygankova O, Anikeeva N, Sykulev Y, Campbell KS. The FcgammaRIIIA (CD16) L48-H\/R polymorphism enhances NK cell-mediated antibody-dependent cellular cytotoxicity by promoting serial killing. Cancer Immunol Res. 2025;13(3):417\u201329.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2174_CR68","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, et al. NSABP B-47\/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020;38(5):444\u201353.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2174_CR69","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMc0801440","volume":"358","author":"S Paik","year":"2008","unstructured":"Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409\u201311.","journal-title":"N Engl J Med"},{"issue":"28","key":"2174_CR70","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1200\/JCO.2009.26.2154","volume":"28","author":"EA Perez","year":"2010","unstructured":"Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010;28(28):4307\u201315.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2174_CR71","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ajpath.2013.07.015","volume":"183","author":"MD Onsum","year":"2013","unstructured":"Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol. 2013;183(5):1446\u201360. https:\/\/doi.org\/10.1016\/j.ajpath.2013.07.015.","journal-title":"Am J Pathol"},{"issue":"1","key":"2174_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10020-019-0108-z","volume":"25","author":"DB Peckys","year":"2019","unstructured":"Peckys DB, Hirsch D, Gaiser T, de Jonge N. Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue. Mol Med. 2019;25(1):42.","journal-title":"Mol Med"},{"issue":"1","key":"2174_CR73","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/imr.13265","volume":"319","author":"CM Van Wagoner","year":"2023","unstructured":"Van Wagoner CM, Rivera-Escalera F, Jaimes-Delgadillo NC, Chu CC, Zent CS, Elliott MR. Antibody-mediated phagocytosis in cancer immunotherapy. Immunol Rev. 2023;319(1):128\u201341. https:\/\/doi.org\/10.1111\/imr.13265.","journal-title":"Immunol Rev"},{"issue":"23","key":"2174_CR74","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1038\/onc.2013.258","volume":"33","author":"J Yang","year":"2014","unstructured":"Yang J, Zhang Z, Chen C, Liu Y, Si Q, Chuang TH, et al. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene. 2014;33(23):3014\u201323.","journal-title":"Oncogene"},{"key":"2174_CR75","doi-asserted-by":"publisher","first-page":"1500570","DOI":"10.3389\/fimmu.2024.1500570","volume":"15","author":"VA Jennings","year":"2024","unstructured":"Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, et al. Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment. Front Immunol. 2024;15:1500570.","journal-title":"Front Immunol"},{"issue":"5","key":"2174_CR76","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1074-7613(01)00134-0","volume":"14","author":"A Suzuki","year":"2001","unstructured":"Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001;14(5):523\u201334.","journal-title":"Immunity"},{"issue":"12","key":"2174_CR77","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.4049\/jimmunol.1102116","volume":"188","author":"DR Soond","year":"2012","unstructured":"Soond DR, Garcon F, Patton DT, Rolf J, Turner M, Scudamore C, et al. Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. J Immunol. 2012;188(12):5935\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1102116.","journal-title":"J Immunol"},{"issue":"2","key":"2174_CR78","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.immuni.2007.12.014","volume":"28","author":"AE Weant","year":"2008","unstructured":"Weant AE, Michalek RD, Khan IU, Holbrook BC, Willingham MC, Grayson JM. Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity. 2008;28(2):218\u201330.","journal-title":"Immunity"},{"issue":"7","key":"2174_CR79","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nri2570","volume":"9","author":"P Bouillet","year":"2009","unstructured":"Bouillet P, O\u2019Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol. 2009;9(7):514\u20139.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2174_CR80","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ni1138","volume":"5","author":"A Martin-Fontecha","year":"2004","unstructured":"Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260\u20135.","journal-title":"Nat Immunol"},{"issue":"10","key":"2174_CR81","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.4049\/jimmunol.154.10.5071","volume":"154","author":"SE Macatonia","year":"1995","unstructured":"Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995;154(10):5071\u20139. https:\/\/doi.org\/10.4049\/jimmunol.154.10.5071.","journal-title":"J Immunol"},{"issue":"5","key":"2174_CR82","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1182\/blood-2008-02-135871","volume":"112","author":"S Agaugue","year":"2008","unstructured":"Agaugue S, Marcenaro E, Ferranti B, Moretta L, Moretta A. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood. 2008;112(5):1776\u201383.","journal-title":"Blood"},{"issue":"8","key":"2174_CR83","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","volume":"101","author":"TA Fehniger","year":"2003","unstructured":"Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052\u20137.","journal-title":"Blood"},{"issue":"1","key":"2174_CR84","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2004-09-3775","volume":"106","author":"C Adam","year":"2005","unstructured":"Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005;106(1):338\u201344.","journal-title":"Blood"},{"issue":"1","key":"2174_CR85","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther. 2024;9(1):302.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2174_CR86","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.4049\/jimmunol.1000328","volume":"186","author":"AC Jaime-Ramirez","year":"2011","unstructured":"Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol. 2011;186(6):3401\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"2174_CR87","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1023\/A:1023381027062","volume":"23","author":"D Agnello","year":"2003","unstructured":"Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O\u2019Shea JJ, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23(3):147\u201361.","journal-title":"J Clin Immunol"},{"issue":"1","key":"2174_CR88","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cjp2.31","volume":"2","author":"A Ling","year":"2016","unstructured":"Ling A, Lundberg IV, Eklof V, Wikberg ML, Oberg A, Edin S, et al. The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. The Journal of Pathology: Clinical Research. 2016;2(1):21\u201331. https:\/\/doi.org\/10.1002\/cjp2.31.","journal-title":"The Journal of Pathology: Clinical Research"},{"issue":"3","key":"2174_CR89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"5795","key":"2174_CR90","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134.","journal-title":"Science"},{"issue":"11","key":"2174_CR91","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2174_CR92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41523-025-00760-9","volume":"11","author":"B Taurelli Salimbeni","year":"2025","unstructured":"Taurelli Salimbeni B, Giudici F, Pescia C, Berton Giachetti PPM, Scafetta R, Zagami P, et al. Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment. NPJ Breast Cancer. 2025;11(1):41.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"2174_CR93","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"2174_CR94","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ncomms1239","volume":"2","author":"OA Haabeth","year":"2011","unstructured":"Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.","journal-title":"Nat Commun"},{"issue":"1-2","key":"2174_CR95","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.imlet.2004.05.003","volume":"94","author":"J Pan","year":"2004","unstructured":"Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, et al. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett. 2004;94(1\u20132):141\u201351.","journal-title":"Immunol Lett"},{"key":"2174_CR96","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","volume":"15","author":"U Boehm","year":"1997","unstructured":"Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749\u201395. https:\/\/doi.org\/10.1146\/annurev.immunol.15.1.749.","journal-title":"Annu Rev Immunol"},{"issue":"3A","key":"2174_CR97","first-page":"1467","volume":"28","author":"B Hildenbrand","year":"2008","unstructured":"Hildenbrand B, Lorenzen D, Sauer B, Hertkorn C, Freudenberg MA, Peters JH, et al. IFN-y enhances T(H)1 polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions. Anticancer Res. 2008;28(3A):1467\u201376.","journal-title":"Anticancer Res"},{"issue":"2-3","key":"2174_CR98","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12026-011-8231-0","volume":"50","author":"SC Lee","year":"2011","unstructured":"Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50(2\u20133):248\u201354. https:\/\/doi.org\/10.1007\/s12026-011-8231-0.","journal-title":"Immunol Res"},{"issue":"3","key":"2174_CR99","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/eji.1830260323","volume":"26","author":"C Heufler","year":"1996","unstructured":"Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol. 1996;26(3):659\u201368.","journal-title":"Eur J Immunol"},{"issue":"10","key":"2174_CR100","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.4049\/jimmunol.154.10.5093","volume":"154","author":"PT Mehrotra","year":"1995","unstructured":"Mehrotra PT, Grant AJ, Siegel JP. Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol. 1995;154(10):5093\u2013102. https:\/\/doi.org\/10.4049\/jimmunol.154.10.5093.","journal-title":"J Immunol"},{"issue":"5","key":"2174_CR101","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.4049\/jimmunol.151.5.2444","volume":"151","author":"PT Mehrotra","year":"1993","unstructured":"Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol. 1993;151(5):2444\u201352. https:\/\/doi.org\/10.4049\/jimmunol.151.5.2444.","journal-title":"J Immunol"},{"issue":"3","key":"2174_CR102","first-page":"133","volume":"11","author":"A Schomburg","year":"1992","unstructured":"Schomburg A, Menzel T, Korfer A, Heer G, Dallmann I, Kirchner H, et al. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2. Nat Immunol. 1992;11(3):133\u201343.","journal-title":"Nat Immunol"},{"issue":"1","key":"2174_CR103","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B Cozar","year":"2021","unstructured":"Cozar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11(1):34\u201344.","journal-title":"Cancer Discov"},{"key":"2174_CR104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","volume":"430","author":"BKR Chaganty","year":"2018","unstructured":"Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNgamma secretion. Cancer Lett. 2018;430:47\u201356.","journal-title":"Cancer Lett"},{"issue":"6","key":"2174_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101420","volume":"297","author":"YL Chen","year":"2021","unstructured":"Chen YL, Cui Y, Liu X, Liu G, Dong X, Tang L, et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy. J Biol Chem. 2021;297(6):101420. https:\/\/doi.org\/10.1016\/j.jbc.2021.101420.","journal-title":"J Biol Chem"},{"issue":"12","key":"2174_CR106","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","volume":"6","author":"F Concha-Benavente","year":"2018","unstructured":"Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6(12):1548\u201360. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0062.","journal-title":"Cancer Immunol Res"},{"key":"2174_CR107","doi-asserted-by":"publisher","first-page":"1133796","DOI":"10.3389\/fimmu.2023.1133796","volume":"14","author":"NA Beelen","year":"2023","unstructured":"Beelen NA, Aberle MR, Bruno V, Olde Damink SWM, Bos GMJ, Rensen SS, et al. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Front Immunol. 2023;14:1133796.","journal-title":"Front Immunol"},{"key":"2174_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000873","author":"JE Park","year":"2020","unstructured":"Park JE, Kim SE, Keam B, Park HR, Kim S, Kim M, et al. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000873.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2174_CR109","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","volume":"110","author":"E Hatjiharissi","year":"2007","unstructured":"Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V\/V and V\/F polymorphism. Blood. 2007;110(7):2561\u20134.","journal-title":"Blood"},{"key":"2174_CR110","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2019.00849","volume":"9","author":"J Garcia-Foncillas","year":"2019","unstructured":"Garcia-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, et al. Distinguishing features of Cetuximab and Panitumumab in colorectal cancer and other solid tumors. Front Oncol. 2019;9:849.","journal-title":"Front Oncol"},{"issue":"1","key":"2174_CR111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","volume":"13","author":"L Egli","year":"2024","unstructured":"Egli L, Kaulfuss M, Mietz J, Picozzi A, Verhoeyen E, Munz C, et al. CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. Exp Hematol Oncol. 2024;13(1):51.","journal-title":"Exp Hematol Oncol"},{"key":"2174_CR112","doi-asserted-by":"publisher","first-page":"34310","DOI":"10.1038\/srep34310","volume":"6","author":"WH Yeap","year":"2016","unstructured":"Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, et al. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2016;6:34310.","journal-title":"Sci Rep"},{"key":"2174_CR113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026849118","author":"R Upton","year":"2021","unstructured":"Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2026849118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2174_CR114","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.1038\/s41598-020-66072-z","volume":"10","author":"S Das Gupta","year":"2020","unstructured":"Das Gupta S, Ndode-Ekane XE, Puhakka N, Pitkanen A. Droplet digital polymerase chain reaction-based quantification of circulating microRNAs using small RNA concentration normalization. Sci Rep. 2020;10(1):9012.","journal-title":"Sci Rep"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02174-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:02:32Z","timestamp":1769382152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02174-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02174-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval and consent were reported in the Materials and Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}